ENTPD1 and cancer: For instance, adenosine signaling is an established factor that dampens the immune response in inflamed tissues and targeting of either adenosine receptors (particularly ADORA2A) or adenosine-synthesizing enzymes (NT5E and ENTPD1) is currently being evaluated in combination with cancer immunotherapies.46